145 related articles for article (PubMed ID: 2757009)
1. Ferrokinetic study of splenic erythropoiesis: relationships among clinical diagnosis, myelofibrosis, splenomegaly, and extramedullary erythropoiesis.
Beguin Y; Fillet G; Bury J; Fairon Y
Am J Hematol; 1989 Oct; 32(2):123-8. PubMed ID: 2757009
[TBL] [Abstract][Full Text] [Related]
2. Analysis of extramedullary erythropoiesis in the spleen by a semiquantitative method using indium-111.
Rojer RA; Mulder NH; Nieweg HO; Edin MR; Beekhuis H; Piers DA; Woldring MG
Acta Med Scand; 1978; 203(6):481-6. PubMed ID: 665315
[TBL] [Abstract][Full Text] [Related]
3. Quantitative studies of splenic erythropoiesis in polycythaemia vera and myelofibrosis.
Pettit JE; Lewis SM; Williams ED; Grafton CA; Bowring CS; Glass HI
Br J Haematol; 1976 Nov; 34(3):465-75. PubMed ID: 990184
[TBL] [Abstract][Full Text] [Related]
4. Development of polycythaemia vera in a patient with myelofibrosis.
Dokal I; Pagliuca A; Deenmamode M; Mufti GJ; Lewis SM
Eur J Haematol; 1989 Jan; 42(1):96-8. PubMed ID: 2914600
[TBL] [Abstract][Full Text] [Related]
5. [Ineffective erythropoiesis in myeloid splenomegaly: the 59Fe test, bone marrow histologic and cytologic data].
Charbord P; Caillou B; Lafleur M; Parmentier C
Nouv Rev Fr Hematol (1978); 1978 Nov; 20(3):443-53. PubMed ID: 754175
[TBL] [Abstract][Full Text] [Related]
6. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Tefferi A
Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
[TBL] [Abstract][Full Text] [Related]
7. The splenomegaly of myeloproliferative disorders: effects on blood volume and red blood count.
Zhang B; Lewis SM
Eur J Haematol; 1989 Mar; 42(3):250-3. PubMed ID: 2924887
[TBL] [Abstract][Full Text] [Related]
8. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
10. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
11. SPLENECTOMY FOR AGNOGENIC MYELOID METAPLASIA AND MYELOFIBROSIS.
FISHMAN N; BALLINGER WF
Arch Surg; 1965 Feb; 90():240-6. PubMed ID: 14232953
[No Abstract] [Full Text] [Related]
12. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Hyun BH; Gulati GL; Ashton JK
Clin Lab Med; 1990 Dec; 10(4):825-38. PubMed ID: 2272176
[TBL] [Abstract][Full Text] [Related]
15. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity.
Zhang B; Lewis SM
Eur J Haematol; 1989 Jul; 43(1):63-6. PubMed ID: 2767243
[TBL] [Abstract][Full Text] [Related]
16. An addition to geographic hematology: chronic myeloproliferative diseases are infrequent in Mexican Mestizos.
Ruiz-Argüelles GJ; López-Martínez B; Lobato-Mendizábal E; Ruiz-Delgado GJ
Int J Hematol; 2002 Jun; 75(5):499-502. PubMed ID: 12095150
[TBL] [Abstract][Full Text] [Related]
17. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
18. [Study of splenic erythropoiesis with radioisotopes in polycythemia vera complicated by myelosclerosis. (Study of 5 cases)].
Vilcu A; Xenakis A; Hossu T; Câmpeanu L; Marcu I; Teitel P
Med Interna (Bucur); 1973 Sep; 25(9):1117-26. PubMed ID: 4792532
[No Abstract] [Full Text] [Related]
19. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of bone marrow imaging with 111indium-transferrin and 99m technetium-colloids in myelofibrosis.
Arrago JP; Rain JD; Vigneron N; Poirier O; Chomienne C; D'Agay MF; Najean Y
Am J Hematol; 1985 Mar; 18(3):275-82. PubMed ID: 3976644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
